|
Drug ↑
|
Title
|
Description
|
Created
|
| |
|
Advancing Evidence in HIV Care: Not Product Specific (General)
|
ViiV Healthcare welcomes investigator-sponsored research that advances understanding of HIV care in a general context, without focusing on any specific product. Research of interest may include real-world effectiveness, safety and tolerability, patient and provider experience, quality of life, healthcare resource use, economic value, and health equity. We encourage innovative approaches and studies across diverse populations that can expand real-world knowledge and inform clinical practice.
|
9/14/2025
|
| |
|
Advancing Evidence in Cabotegravir for HIV Prevention (General)
|
ViiV Healthcare welcomes investigator-sponsored research that advances understanding of cabotegravir in HIV prevention across a wide range of scientific priorities. Research of interest may include real-world effectiveness, safety and tolerability, patient and provider experience, quality of life, healthcare resource use, economic value, and health equity. We encourage innovative approaches and studies in diverse populations that can expand real-world knowledge and inform clinical practice.
|
9/14/2025
|
| |
|
Advancing Evidence in Cabotegravir Treatment (General)
|
ViiV Healthcare welcomes investigator-sponsored research that advances understanding of cabotegravir in HIV treatment across a wide range of scientific priorities. Research of interest may include real-world effectiveness, safety and tolerability, patient and provider experience, quality of life, healthcare resource use, economic value, and health equity. We encourage innovative approaches and studies in diverse populations that can expand real-world knowledge and inform clinical practice.
|
9/14/2025
|
| |
|
Clinically Relevant Outcomes Beyond Virologic Suppression
|
This AOI seeks evidence on the outcomes and value of CAB + RPV LA beyond maintaining virologic suppression. Focus may include adherence, persistence, patient-reported outcomes, impact on quality of life, stigma reduction, engagement in care, and the broader health impacts associated with increased touchpoints with healthcare providers afforded by CAB + RPV LA (i.e., treatment optimization of comorbid conditions and preventative healthcare interventions such as vaccinations, cancer screenings, and sexual health screenings).
|
9/8/2026
|
| |
|
Evidence in Populations Under‑Represented in Clinical Trials
|
Evidence is sought to understand the use, outcomes, and lived experiences of individuals receiving CAB + RPV LA, particularly among populations not represented or underrepresented in pivotal clinical trials.
Populations of Interest is open and may include, but not limited to: women across the age and reproductive continuum, individuals who have fallen out of care (where CAB + RPV LA may facilitate re-engagement in care opportunities), adherence‑challenged individuals, long‑term survivors (i.e., individuals having a HIV diagnosis prior to 1996), older adults (EU region only), treatment naive individuals switching soon after attaining initial viral suppression with oral ART.
|
9/8/2026
|
| |
|
Economics and Health System Impact
|
Evidence is needed to understand the economic and health system implications of CAB + RPV LA compared to oral ART, including downstream impacts of adherence differences, healthcare resource utilization, and implications for public health outcomes.
|
9/8/2026
|
| |
|
Efficacy and Safety of DTG/3TC among Treatment-Naïve Individuals
|
ViiV Healthcare welcomes investigator-sponsored research that advances understanding of DTG/3TC in the treatment of HIV among treatment-naïve individuals. Research of interest may include real-world effectiveness, barrier to resistance, safety and tolerability, patient and provider experience, and health-related quality of life. We encourage innovative approaches and studies across diverse populations that can expand real-world knowledge and inform clinical practice.
|
9/14/2025
|
| |
|
Efficacy and Safety of DTG/3TC in Pregnancy
|
ViiV Healthcare welcomes investigator-sponsored research that advances understanding of the efficacy and safety of DTG/3TC in pregnancy. Research of interest may include real-world effectiveness, safety and tolerability, patient and provider experience, and health-related quality of life. We encourage innovative approaches and studies across diverse populations that can expand real-world knowledge and inform clinical practice.
|
9/14/2025
|
| |
|
Advancing Evidence in Dolutegravir/Lamivudine (DTG/3TC) Treatment (General)
|
ViiV Healthcare welcomes investigator-sponsored research that advances understanding of DTG/3TC in the treatment of HIV. Research of interest may include real-world effectiveness, safety and tolerability, patient and provider experience, and health-related quality of life. We encourage innovative approaches and studies across diverse populations that can expand real-world knowledge and inform clinical practice.
|
9/14/2025
|
| |
|
Advancing Evidence in HIV Treatment: Using other VH Product besides Cabotegravir and Dolutegravir/Lamivudine (General)
|
ViiV Healthcare welcomes investigator-sponsored research that advances understanding of HIV treatment using other VH products besides Cabotegravir and Dolutegravir/Lamivudine. Research of interest may include real-world effectiveness, safety and tolerability, patient and provider experience, quality of life, healthcare resource use, economic value, and health equity. We encourage innovative approaches and studies across diverse populations that can expand real-world knowledge and inform clinical practice.
|
9/14/2025
|
Just a moment, the page is loading...